Paul Clopton
About
In The Last Decade
Paul Clopton
84 papers receiving 4.8k citations
Hit Papers
Peers
Comparison fields: 5 of 154
- Cardiology and Cardiovascular Medicine 2.2k
- Epidemiology 832
- Surgery 790
- Molecular Biology 487
- Oncology 425
Countries citing papers authored by Paul Clopton
This map shows the geographic impact of Paul Clopton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Clopton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Clopton more than expected).
Fields of papers citing papers by Paul Clopton
This network shows the impact of papers produced by Paul Clopton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Clopton. The network helps show where Paul Clopton may publish in the future.
Co-authorship network of co-authors of Paul Clopton
This figure shows the co-authorship network connecting the top 25 collaborators of Paul Clopton. A scholar is included among the top collaborators of Paul Clopton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Clopton. Paul Clopton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 4 | |
| 3 | 252 | |
| 4 | 45 | |
| 5 | Abstract 16890: Ablation of Atrial Fibrillation Rotors and Focal Sources Improves Outcome Over Conventional Ablation Alone in Independent Laboratories: Multicenter Validation of Focal Impulse and Rotor Modulation (FIRM) | 3 |
| 6 | 26 | |
| 7 | 154 | |
| 8 | Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease breakdown → | 767 |
| 9 | Treatment of Atrial Fibrillation by the Ablation of Localized Sources breakdown → | 782 |
| 10 | 4 | |
| 11 | 7 | |
| 12 | 85 | |
| 13 | A NEW THERAPY FOR NONALCOHOLIC FATTY LIVER DISEASE AND DIABETES? INT-747-THE FIRST FXR HEPATIC THERAPEUTIC STUDY | 18 |
| 14 | 103 | |
| 15 | 19 | |
| 16 | 79 | |
| 17 | 52 | |
| 18 | 49 | |
| 19 | 10 | |
| 20 | 33 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.